Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-05-17
2005-05-17
Shameem, Golam M M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S465000, C548S469000, C548S537000, C548S950000, C546S192000, C544S359000, C514S423000
Reexamination Certificate
active
06894072
ABSTRACT:
The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.
REFERENCES:
patent: 5712145 (1998-01-01), Houghton et al.
patent: 381 216 (1990-08-01), None
patent: WO 8904669 (1989-06-01), None
patent: WO 9814181 (1998-04-01), None
patent: WO 9817679 (1998-04-01), None
patent: WO 9822496 (1998-05-01), None
patent: WO 9907734 (1999-02-01), None
patent: WO 0009543 (2000-02-01), None
patent: WO 0009558 (2000-02-01), None
patent: WO 0174768 (2001-10-01), None
patent: WO 0208198 (2002-01-01), None
patent: WO 0208244 (2002-01-01), None
patent: WO 0208256 (2002-01-01), None
Gumber, et al, Ann Intern Med. 1995, 123, 615-620.*
Leveque, et al, CMLS, 2002, 59, 909-919.*
Pizzi et al., “Molecular Model of the Specificity Pocket of the Hepatitis C. Virus Protease: Implications for the Substrate Recognition”,Proc. Natl. Acad. Sci. (USA), 91: 888-892 (1994).
Failla et al., “Redesigning the Substrate Specificity of the Hepatitis C Virus NS3 Protease”,Folding&Design, 1(1): 35-42 (1996).
Kolykhavlov et al., “Specificity of the Hepatitis C Virus NS3 Serine Protease: Effects of Substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B Cleavage Sites on Polyprotein Processing”,J. Virology, 68(11): 7525-7533 (1994).
Komoda et al., “Substrate Requirements of Hepatitis C Virus Serine Proteinase for Intermolecular Polypeptide Cleavage inEscherichia Coli”, J. Virology, 68(11): 7351-7357 (1994).
Landro et al., “Mechanistic Role of an NS4A Peptide Cofactor with the Truncated NS3 Protease of Hepatits C Virus: Elucidaiton of the NS4A Stimulatory Effect via Kinetic Analysis and Inhibitor Mapping”,Biochemistry, 36: 9340-9348 (1997).
Ingallinella et al., “Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products”Biochemistry, 37: 8906-8914 (1998).
Llinàs-Brunet et al., “Studies on the C-Terminal of Hexapeptide Inhibitors of the Hepatitis C Virus Serine Protease”,Bioorg. Med. Chem. Lett., 8: 2719-2724 (1998).
Matin et al., “Design of Selective Eglin Inhibitors of HCV NS3 Proteinase”,Biochemistry, 37: 11459-11468 (1998).
Dimasi et al., “Characterization of Engineered Hepatitis C Virus NS3 Protease Inhibitors Affinity Selected from Human Pancreatic Secretory Trypsin Inhibitor and Minibody Repertoires”,J. Virology, 71(10): 7461-7469 (1997).
Martin et al., “Affinity Selection of a Camelized VHDomain Antibody Inhibitor of Hepatitis C Virius NS3 Protease”,Protein Engineering, 10(5): 607-614 (1997).
Elzouki et al., “Serine Protease Inhibitors in Patients with Chronic Viral Hepatitis”,J. Hepatology, 27: 42-48 (1997).
BioWorld Today, 9(217): 4 (Nov. 10, 1998).
Berenguer et al., “Hepatitis B and C Viruses: Molecular Identification and Targeted Antiviral Therapies”,Proc. Assoc. Amer. Physicians, 110(2): 98-112 (1998).
Hoofnagle et al., “The Treatment of Chronic Viral Hepatitis”,N. Engl. J. Med., 336(5): 347-356 (1997).
R. Zhang et al., “Design Synthesis and Evaluation of Poly-L-Proline Type-II Peptide Mimics Based on the 3-Azabicyclo[3.1.0]hexane System”,J. Org. Chem., 64: 330-331 (1999).
D. L. Sali et al., “Serine Protease of Hepatitis C Virus Expressed in Insect Cells as the NS3/4A Complex”, Biochemistry, 37: 3392-3401 (1998).
K. Barlos et al., “2-Chlorothityl Chloride Resin . . . Studies on anchoring of Fmoc-amino acids and peptide cleavage”, Int. J. Pept. Protein Res., 37: 513-520 (1991).
K. Holmberg et al., “Ester Synthesis with Dicyclohexylcarbodiimide Improved by Acid Catalysts”, Acta. Chem Scand., B33: 410-412 (1979).
A. Marchetti et al., “Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease”,Synlett, S1: 1000-1002 (1999).
W Han et al., “α-Ketoamides, α-Ketoesters and α-Diketones as HCV NS3 Protease Inhibitors”,Bioorganic&Medicinal Chem. Lett., 10: 711-713 (2000).
S. Agrawal et al., “Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay”, Hepatology Supplement to vol. 30 (No. 4, Part 2, Oct. 1999), Abstract No. 615 (Proceedings of AASLD 50thAnnual Meeting, Dallas, Texas, Nov. 5-9, 1999.
D. L. Hughs, “The Mitsunobu Reaction”,Organic Reactions, 42: 335-395 (1992).
R. F. Heck, “Palladium-Catalyzed Vinylation of Organic Halides”,Organic Reactions, 27: 345-391 (1989).
Arasappan Ashok
Bennett Frank
Bogen Stephane L.
Chen Kevin X.
Girijavallabhan Viyyoor M.
Kalyanaraman Palaiyur S.
Schering Corporation
Shameem Golam M M
LandOfFree
Compounds as NS3-serine protease inhibitors of hepatitis C... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds as NS3-serine protease inhibitors of hepatitis C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds as NS3-serine protease inhibitors of hepatitis C... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3409632